Back to results
US 2011/0237645 A1Published application
USE OF RNAi TECHNOLOGY TO INHIBIT ASIC3
AssigneeUniversity of Iowa Research Foundation
InventorsKATHLEEN A. SLUKA, ROXANNE Y. WALDER
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeUniversity of Iowa Research Foundation
InventorsKATHLEEN A. SLUKA, ROXANNE Y. WALDER
Estimating the term…
In vitro studies using cells transfected with acid-sensing ion channel 3 (ASIC3) or acid-sensing ion channel 1 (ASIC1) cDNA, demonstrated that the miRNAs against mouse ASIC3 (miR844 and miR847) selectively inhibit mouse ASIC3, but not ASIC1 as detected by protein expression and responses to pH. When the RNAi agents, miR844 or miR847, were used in vivo, delivered into the muscle of mice using a replication-defective herpes simplex viral (HSV-1) vector, primary and secondary hyperalgesia were reduced after carrageenan-induced muscle inflammation. Accordingly, the present invention provides RNAi agents that target ASIC3, methods of preparing such RNAi agents, and methods of using them to modulate in a cell the level of ASIC3 or activity of an ASIC including at least one ASIC3. Modulation of ASIC3 activity or levels can be used for different purposes such as treating pain associated with the expression of ASIC3 and the like.
An RNAi agent targeted to a transcript that encodes acid-sensing ion channel 3 (ASIC3) for decreasing expression or activity of ASIC3.
A method of treating or preventing a disease, disorder or condition is associated with, or mediated by a decrease in extracellular pH, comprising:
A method of decreasing expression or activity of ASIC3 in a cell by contacting a cell expressing acid-sensing ion channel 3 (ASIC3) with an effective amount of a RNAi agent targeted to a transcript that encodes ASIC3 for a sufficient amount of time to decrease ASIC3 expression or activity.
An isolated oligonucleotide comprising a polynucleotide sequence comprising about 12 to 25 nucleotides in length sufficiently complementary to a microRNA target sequence of ASIC3, wherein the oligonucleotide is capable of decreasing ASIC3 expression or activity.
An isolated single stranded microRNA molecule, said molecule comprising the sequence of bases identified in SEQ. ID. NOS:1-27 or the complement thereof wherein the molecule is capable of decreasing ASIC3 expression or activity.
Dependencies are inferred from the claim text.